Year: 2018
Type: review
Abstract: Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of unknown cause that occurs primarily in older adults. Its prevalence and incidence have appeared to be increasing over the last decades. Despite its unknown nature, several genetic and environmental factors have been associated with IPF. Moreover, its natural history is variable, but could change depending on the currently suggested phenotypes: rapidly progressive IPF, familial, combined pulmonary fibrosis and emphysema, pulmonary hypertension, and that associated with connective tissue diseases. Early recognition and accurate staging are likely to improve outcomes and induce a prompt initiation of antifibrotics therapy. Treatment is expected to be more effective in the early stages of the disease, while developments in treatment aim to improve the current median survival of 3⁻4 years after diagnosis.
Source: Medical Sciences
Institutions: Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Centro de Investigación Biomédica en Red, Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Universidad Autónoma de Madrid
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, interstitial lung disease, epidemiology, incidence and prevalence, natural history (disease), disease phenotypes, familial pulmonary fibrosis, combined pulmonary fibrosis and emphysema, pulmonary hypertension, connective tissue diseases, antifibrotic therapy, disease staging, survival
Open Access status: gold
Estimated APC paid: $1,689
OpenAlex ID: W2902041602
